GlassScriptPhysician profile
William Chongwon Choe
NPI 1134146053
$20,493.87
in general payments reported to CMS, 2019-2025
22 companies · $2,456 in 2025
The $2,456 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,991 · 2020: $492 · 2021: $519 · 2022: $5,985 · 2023: $4,702 · 2024: $3,349 · 2025: $2,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,770 · Travel and Lodging: $2,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,770.35 |
| Travel and Lodging | $2,736.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $13,142.86 | 2019-2025 | Aveir, Ensite, Ensite Precision |
| Impulse Dynamics (USA) INC. | $2,033.76 | 2022-2025 | Optimizer, Optimizer |
| Boston Scientific Corporation | $1,959.81 | 2019-2025 | Watchman Access System, General - Therapies, Watchman |
| Medtronic, INC. | $1,173.30 | 2023-2025 | Micra, Affera Mapping System, Cobalt Dr Mri Surescan |
| Medtronic Vascular, INC. | $541.08 | 2019-2020 | |
| Pfizer INC. | $323.99 | 2019-2025 | |
| Atricure, INC. | $247.11 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Shockwave Medical, INC | $209.90 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Biotronik INC. | $167.86 | 2023 | Acticor 7 Vr-T Dx |
| Cardiva Medical, INC. | $142.04 | 2022-2023 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Novartis Pharmaceuticals Corporation | $85.37 | 2025 | |
| Abiomed | $73.57 | 2024-2025 | Impella |
| Cardiofocus, INC. | $68.69 | 2019 | |
| Sanofi-Aventis U.S. LLC | $64.92 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $49.85 | 2019-2023 | Eliquis |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $49.82 | 2019-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $49.09 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $29.57 | 2019-2020 | |
| Biosense Webster, INC. | $28.03 | 2019 | |
| Lilly USA, LLC | $25.10 | 2025 | Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $17.29 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.86 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Choe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.